Mucin as a therapeutic target in pseudomyxoma peritonei

Haroon A. Choudry, Mark E. O'Malley, Zong Sheng Guo, Herbert J. Zeh, David L. Bartlett

Research output: Contribution to journalReview article

15 Scopus citations


Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. © 2012 Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)911-917
Number of pages7
JournalJournal of Surgical Oncology
Issue number7
StatePublished - Dec 1 2012
Externally publishedYes


  • chemoperfusion
  • goblet cells
  • mucin
  • pseudomyxoma peritonei
  • targeted therapy
  • transcriptional regulation

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Mucin as a therapeutic target in pseudomyxoma peritonei'. Together they form a unique fingerprint.

  • Cite this

    Choudry, H. A., O'Malley, M. E., Guo, Z. S., Zeh, H. J., & Bartlett, D. L. (2012). Mucin as a therapeutic target in pseudomyxoma peritonei. Journal of Surgical Oncology, 106(7), 911-917.